Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
iShares Core 60/40 Balanced Allocation ETF stock logo
AOR
iShares Core 60/40 Balanced Allocation ETF
$61.57
+0.4%
$59.23
$52.97
$61.61
$2.50B0.61236,908 shs208,955 shs
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
$2.57
+4.9%
$1.86
$0.81
$3.11
$82.90M-0.27148,107 shs53,064 shs
Saratoga Investment Corp stock logo
SAR
Saratoga Investment
$24.81
+0.5%
$24.39
$21.10
$26.49
$379.20M0.6893,464 shs119,665 shs
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
iShares Core 60/40 Balanced Allocation ETF stock logo
AOR
iShares Core 60/40 Balanced Allocation ETF
0.00%+2.23%+3.16%+6.53%+8.90%
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
0.00%+3.38%+32.70%+92.91%+105.88%
Saratoga Investment Corp stock logo
SAR
Saratoga Investment
0.00%+0.86%-0.66%-2.47%+8.70%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
iShares Core 60/40 Balanced Allocation ETF stock logo
AOR
iShares Core 60/40 Balanced Allocation ETF
N/AN/AN/AN/AN/AN/AN/AN/A
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
2.5999 of 5 stars
3.53.00.00.03.31.70.0
Saratoga Investment Corp stock logo
SAR
Saratoga Investment
1.5156 of 5 stars
1.03.01.70.02.40.81.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
iShares Core 60/40 Balanced Allocation ETF stock logo
AOR
iShares Core 60/40 Balanced Allocation ETF
0.00
N/AN/AN/A
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
3.00
Buy$7.00172.37% Upside
Saratoga Investment Corp stock logo
SAR
Saratoga Investment
2.00
Hold$24.25-2.26% Downside

Current Analyst Ratings Breakdown

Latest APTA, OKYO, AOR, and SAR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/9/2025
Saratoga Investment Corp stock logo
SAR
Saratoga Investment
Compass Point
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral$25.25 ➝ $24.25
5/13/2025
Saratoga Investment Corp stock logo
SAR
Saratoga Investment
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageNeutral$23.50
5/12/2025
Saratoga Investment Corp stock logo
SAR
Saratoga Investment
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold
5/5/2025
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$7.00 ➝ $7.00
(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
iShares Core 60/40 Balanced Allocation ETF stock logo
AOR
iShares Core 60/40 Balanced Allocation ETF
N/AN/AN/AN/AN/AN/A
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
N/AN/AN/AN/A($0.20) per shareN/A
Saratoga Investment Corp stock logo
SAR
Saratoga Investment
$148.85M2.56$2.74 per share9.07$27.37 per share0.91
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
iShares Core 60/40 Balanced Allocation ETF stock logo
AOR
iShares Core 60/40 Balanced Allocation ETF
N/AN/A19.83N/AN/AN/AN/AN/A
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
-$16.83MN/A0.00N/AN/AN/AN/AN/A8/12/2025 (Estimated)
Saratoga Investment Corp stock logo
SAR
Saratoga Investment
$28.09M$2.0412.168.33N/A18.87%14.04%4.40%7/8/2025 (Estimated)

Latest APTA, OKYO, AOR, and SAR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/8/2025Q1 2026
Saratoga Investment Corp stock logo
SAR
Saratoga Investment
$0.72N/AN/AN/A$32.75 millionN/A
5/7/2025Q4 2025
Saratoga Investment Corp stock logo
SAR
Saratoga Investment
$0.77$0.56-$0.21-$0.05$32.86 million$31.30 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
iShares Core 60/40 Balanced Allocation ETF stock logo
AOR
iShares Core 60/40 Balanced Allocation ETF
$1.552.52%N/AN/AN/A
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
N/AN/AN/AN/AN/A
Saratoga Investment Corp stock logo
SAR
Saratoga Investment
$3.0012.09%N/A147.06%N/A

Latest APTA, OKYO, AOR, and SAR Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
6/16/2025
Saratoga Investment Corp stock logo
SAR
Saratoga Investment
monthly$0.2512.3%9/4/20259/4/20259/24/2025
6/13/2025
Saratoga Investment Corp stock logo
SAR
Saratoga Investment
monthly$0.2512.3%9/4/20259/4/20259/24/2025
5/1/2025
Saratoga Investment Corp stock logo
SAR
Saratoga Investment
$0.2512.31%5/6/20255/7/20255/22/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
iShares Core 60/40 Balanced Allocation ETF stock logo
AOR
iShares Core 60/40 Balanced Allocation ETF
N/AN/AN/A
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
N/A
0.28
N/A
Saratoga Investment Corp stock logo
SAR
Saratoga Investment
0.13
0.29
0.29

Institutional Ownership

CompanyInstitutional Ownership
iShares Core 60/40 Balanced Allocation ETF stock logo
AOR
iShares Core 60/40 Balanced Allocation ETF
N/A
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
2.97%
Saratoga Investment Corp stock logo
SAR
Saratoga Investment
19.09%

Insider Ownership

CompanyInsider Ownership
iShares Core 60/40 Balanced Allocation ETF stock logo
AOR
iShares Core 60/40 Balanced Allocation ETF
N/A
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
40.46%
Saratoga Investment Corp stock logo
SAR
Saratoga Investment
12.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
iShares Core 60/40 Balanced Allocation ETF stock logo
AOR
iShares Core 60/40 Balanced Allocation ETF
N/A40.60 millionN/ANot Optionable
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
733.84 million20.15 millionNot Optionable
Saratoga Investment Corp stock logo
SAR
Saratoga Investment
3,21115.36 million13.52 millionOptionable

Recent News About These Companies

SAR - Saratoga Investment Corp Chart - Morningstar

New MarketBeat Followers Over Time

Media Sentiment Over Time

iShares Core 60/40 Balanced Allocation ETF stock logo

iShares Core 60/40 Balanced Allocation ETF NYSEARCA:AOR

$61.57 +0.24 (+0.39%)
As of 04:10 PM Eastern

iShares Growth Allocation ETF, formerly iShares S&P Growth Allocation Fund (the Fund), is an open-end management investment company. The Fund seeks investment results that correspond generally to the price and yield performance of the S&P Target Risk Growth Index (the Growth Allocation Index). The Growth Allocation Index seeks to measure the performance of an asset allocation strategy targeted to a growth-focused risk profile. The Fund is designed for investors seeking moderate capital appreciation and opportunity for current income and capital preservation. The Fund's investment advisor is BlackRock Fund Advisors.

OKYO Pharma stock logo

OKYO Pharma NASDAQ:OKYO

$2.57 +0.12 (+4.90%)
As of 04:00 PM Eastern

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom.

Saratoga Investment stock logo

Saratoga Investment NYSE:SAR

$24.81 +0.13 (+0.53%)
As of 03:58 PM Eastern

Saratoga Investment Corp. is a business development company specializing in leveraged and management buyouts, acquisition financings, growth financings, recapitalization, debt refinancing, and transitional financing transactions at the lower end of middle market companies. It structures its investments as debt and equity by investing through first and second lien loans, mezzanine debt, co-investments, select high yield bonds, senior secured bonds, unsecured bonds, and preferred and common equity. The firm prefers to invest in aerospace, automotive aftermarket and services, business products and services, consumer products and services, education, environmental services, industrial services, financial services, food and beverage, healthcare products and services, logistics, distribution, manufacturing, restaurants services, food services, software services, technology services, specialty chemical, media and telecommunications. It seeks to invest in the United States. The firm primarily invests $5 million to $50 million in companies having EBITDA of $2 million or greater and revenues of $8 million to $250 million. The firm prefer to take a majority stake. It invests through direct lending as well as participation in loan syndicates. The firm was formerly known as GSC Investment Corp. Saratoga Investment Corp. was formed on 2007 and is based in New York, New York with an additional office in Florham Park, New Jersey.